Previous 10 | Next 10 |
PORTLAND, Maine, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health a...
PORTLAND, Maine, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health a...
PORTLAND, Maine, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
PORTLAND, Maine, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
ImmuCell ( NASDAQ: ICCC ) said its Q3 sales declined 7% Y/Y according to preliminary results for the period ended Sept. 30. Q3 sales are expected to be $4.80M, compared to $5.15M in Q3 2021. The company's Q2 revenue had declined -15.0% Y/Y to $3.86M. "We...
PORTLAND, Maine, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health...
The following slide deck was published by ImmuCell Corporation in conjunction with their 2022 Q2 earnings call. For further details see: ImmuCell Corporation 2022 Q2 - Results - Earnings Call Presentation
ImmuCell Corporation (ICCC) Q2 2022 Earnings Conference Call August 12, 2022 09:00 ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management ...
ImmuCell press release ( NASDAQ: ICCC ): Q2 GAAP EPS of -$0.09. Revenue of $3.86M (-15.0% Y/Y). For further details see: ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
News, Short Squeeze, Breakout and More Instantly...
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the he...
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health an...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...